Loading...
On June 20, 2014, the FDA announced approval of tedizolid (Sivextro) for treatment of acute bacterial skin and skin-structure infections (ABSSIs) caused by Staphylococcus aureus, Streptococcus pyogenes, various Streptococcus species, or Enterococcus faecalis. In two phase III, randomized, controlled trials totaling >1300 patients, 6 days of tedizolid (200 mg daily) was noninferior to 10 days of linezolid (600 mg twice daily). Additional phase III trials are under way for treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Tedizolid is available in intravenous and oral formulations and — like the structurally related linezolid — has high oral bioavailability. The most common adverse effects in clinical trials were na…